Nanoparticulate Systems for Treatment of Glioblastoma by Intranasal Administration: A Non-Invasive Approach

Recently, nanobiomedicine a fascinating topic with enormous potential to transform cancer detection and treatment methods has emerged from the nexus of nanotechnology and biomedical research. The goal of this novel combination of biology, medicine, and nanotechnology is to develop therapeutic and diagnostic agents that are safer and more effective, especially in the field of theranostics for different types of cancer. The most prevalent malignant primary brain tumor is glioblastoma multiforme (GBM), which occurs in 3.19 cases per 100,000 person years. With a 5-year survival rate of 7.2%, glioblastoma multiforme (GBM), a WHO grade IV glioma, is the most prevalent malignant primary brain tumor. Treatment has been extremely difficult because of its highly infiltrative nature, genetic variability, and blood brain barrier (BBB) protection. Chemoradiotherapy and surgical excision are the usual treatments for GBMs. Resistance to all available treatment approaches is enhanced by the strong DNA repair and self-renewing properties of glioblastoma cells and glioma initiating cells (GICs), respectively.